14/10/2026
𝗡𝗶𝘁𝗿𝗼𝘀𝗮𝗺𝗶𝗻𝗲𝘀 & 𝗡𝗗𝗦𝗥𝗜𝘀: 𝗶𝘀 𝘆𝗼𝘂𝗿 𝗽𝗿𝗼𝗱𝘂𝗰𝘁 𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁?
Since 2018, NDMA and NDEA found in sartans, ranitidine and metformin have pushed regulators to act.
📌 All pharmaceutical manufacturers must now assess and control nitrosamine impurities in APIs and finished drug products per ICH M7 and the FDA Nitrosamine Guidance Revision 2 (September 2024).
🔬 𝗪𝗵𝗮𝘁 𝘄𝗲 𝘁𝗲𝘀𝘁
✓ 13+ named nitrosamines incl. NDMA, NDEA, NMBA, NDIPA, NEIPA, NDBA, NMPA
✓ Drug-specific NDSRIs per USFDA guidance, CPCA applied where no TD50 exists
✓ Volatile nitrosamines by GC-MS/MS and GC headspace
✓ APIs, finished formulations and excipients
⚙️ 𝗛𝗼𝘄 𝘄𝗲 𝗱𝗼 𝗶𝘁
✓ 9 LC-MS/MS units across Delhi, Bangalore and Manesar
✓ Method development and full validation per ICH Q2(R2)
✓ ICH M7 risk assessment support for CDSCO, USFDA and EMA filings
⏱️ 𝗧𝗔𝗧: 𝟰–𝟲 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗱𝗮𝘆𝘀 (rush 2–4 working days). NDSRI method development + validation: 3–5 weeks.
📍 Delhi · Bangalore · Gurugram
📲 Call Us & WhatsApp your sample details for a quote: +91-7428116100
🔗 https://aurigaresearch.com/testing/pharmaceutical-testing/nitrosamine-testing/?utm_source=linkedin&utm_medium=social&utm_campaign=nitrosamine_2026